IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. More Details
Adequate balance sheet with proven track record.
Share Price & News
How has IDEXX Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IDXX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IDXX's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IDXX exceeded the US Medical Equipment industry which returned 20.2% over the past year.
Return vs Market: IDXX exceeded the US Market which returned 22.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is IDEXX Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StThis Insider Has Just Sold Shares In IDEXX Laboratories, Inc. (NASDAQ:IDXX)
2 months ago | Simply Wall StResults: IDEXX Laboratories, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
3 months ago | Simply Wall StCan IDEXX Laboratories (NASDAQ:IDXX) Prolong Its Impressive Returns?
Is IDEXX Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IDXX ($496.44) is trading above our estimate of fair value ($157.53)
Significantly Below Fair Value: IDXX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDXX is poor value based on its PE Ratio (85.3x) compared to the US Medical Equipment industry average (55.7x).
PE vs Market: IDXX is poor value based on its PE Ratio (85.3x) compared to the US market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: IDXX is poor value based on its PEG Ratio (5.8x)
Price to Book Ratio
PB vs Industry: IDXX is overvalued based on its PB Ratio (96.1x) compared to the US Medical Equipment industry average (5.4x).
How is IDEXX Laboratories forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDXX's forecast earnings growth (14.7% per year) is above the savings rate (2%).
Earnings vs Market: IDXX's earnings (14.7% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: IDXX's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDXX's revenue (10.5% per year) is forecast to grow slower than the US market (10.5% per year).
High Growth Revenue: IDXX's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDXX's Return on Equity is forecast to be high in 3 years time
How has IDEXX Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDXX has high quality earnings.
Growing Profit Margin: IDXX's current net profit margins (19.2%) are higher than last year (18%).
Past Earnings Growth Analysis
Earnings Trend: IDXX's earnings have grown significantly by 20.6% per year over the past 5 years.
Accelerating Growth: IDXX's earnings growth over the past year (17.6%) is below its 5-year average (20.6% per year).
Earnings vs Industry: IDXX earnings growth over the past year (17.6%) exceeded the Medical Equipment industry -0.3%.
Return on Equity
High ROE: Whilst IDXX's Return on Equity (112.83%) is outstanding, this metric is skewed due to their high level of debt.
How is IDEXX Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: IDXX's short term assets ($868.7M) exceed its short term liabilities ($526.8M).
Long Term Liabilities: IDXX's short term assets ($868.7M) do not cover its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: IDXX's debt to equity ratio (204.8%) is considered high.
Reducing Debt: IDXX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IDXX's debt is well covered by operating cash flow (64.7%).
Interest Coverage: IDXX's interest payments on its debt are well covered by EBIT (19.9x coverage).
What is IDEXX Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDXX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDXX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDXX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Mazelsky (59 yo)
Mr. Jonathan J. Mazelsky, also known as Jay, has been President, Chief Executive Officer and Director at IDEXX Laboratories, Inc. since October 23, 2019. Mr. Mazelsky was an Interim President and Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD7.42M) is about average for companies of similar size in the US market ($USD10.55M).
Compensation vs Earnings: Jay's compensation has increased by more than 20% in the past year.
|CFO, Executive VP & Treasurer||7yrs||US$3.94m||0.050% |
|Senior VP||no data||US$1.81m||0.0010% |
|Chief Marketing Officer & Senior VP||1yr||US$2.70m||0.012% |
|Senior Advisor & Director||19yrs||US$8.31m||0.79% |
|Executive VP and GM of Reference Laboratories & Information Technology||1yr||US$1.47m||0.0051% |
|Senior Vice President of Worldwide Operations||3.33yrs||no data||no data|
|Senior Director of Accounting & Financial Reporting||6yrs||no data||no data|
|Senior VP & Chief Technology Officer||5.75yrs||no data||no data|
|Senior VP & Chief Information Officer||4.92yrs||no data||no data|
|Senior VP & Chief Human Resources Officer||10.42yrs||US$1.31m||0.015% |
|Executive VP & Chief Commercial Officer||1yr||no data||0.021% |
Experienced Management: IDXX's management team is considered experienced (3.3 years average tenure).
|Senior Advisor & Director||19yrs||US$8.31m||0.79% |
|Independent Director||8.5yrs||US$312.48k||0.012% |
|Independent Director||6.83yrs||US$307.48k||0.0034% |
|Independent Director||5.5yrs||US$303.48k||0.00036% |
|Independent Director||3.5yrs||US$287.48k||0% |
|Independent Director||17.5yrs||US$298.48k||0.017% |
|Independent Non-Executive Chairman||1.17yrs||US$362.81k||0.0080% |
|Independent Director||7.5yrs||US$287.48k||0.010% |
|Independent Director||1.5yrs||US$208.76k||no data|
|Independent Director||0.17yr||no data||no data|
Experienced Board: IDXX's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IDXX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IDEXX Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: IDEXX Laboratories, Inc.
- Ticker: IDXX
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$42.346b
- Shares outstanding: 85.30m
- Website: https://www.idexx.com
Number of Employees
- IDEXX Laboratories, Inc.
- One IDEXX Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IDXX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 1991|
|IX1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 1991|
|IDXX||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jun 1991|
|0J8P||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 1991|
|I1DX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 5 REPR 1 COM||BR||BRL||Jan 2020|
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and wate...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/21 23:41|
|End of Day Share Price||2021/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.